Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Jade Biosciences, Inc. Common Stock

JBIO

Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Last trade $14.95
Day change -$0.385 (-2.51%)
Day range $14.64 – $16.23
Volume 1,364,622
Market cap $1.06B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.06B
Price / earnings
—
Price / book
2.41×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.06×

Profitability

Earnings per share
-$1.78
Return on assets
-26.05%
Return on equity
-27.96%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
14.93×
Quick ratio
14.93×
Cash ratio
3.4×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$110.21M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for JBIO, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025
Revenue$0$0$0$0
Cost of revenue$0$0$0$0
Gross profit$0$0$0$0
Selling, general and administrative$8.85M$7.39M$5.39M$5.23M
Research and development$50.07M$36.05M$22.01M$22.55M
Total operating expenses$58.92M$43.45M$27.4M$27.78M
Operating income-$58.92M-$43.45M-$27.4M-$27.78M
Interest expense$3.23M$3.1M$0$1.83M
Income before taxes-$55.75M-$40.35M-$25.18M-$32.13M
Income taxes$15K$16K$0$0
Net income-$55.77M-$40.37M-$25.18M-$32.13M
Net income attributable to common shareholders-$46.21M-$33.13M-$19.09M-$24.55M
EBITDA-$58.91M-$43.44M-$27.39M-$27.77M
Basic earnings per share-$0.76-$0.57-$0.48-$0.86
Diluted earnings per share-$0.76-$0.57-$0.48-$0.86

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

Jade Biosciences, Inc. (Nasdaq: JBIO) announced the appointment of Dr. Mark Eisner, M.D., M.P.H., to its Board of Directors effective June 25, 2026. Dr. Eisner brings over 25 years of leadership experience in clinical development and immunology, including previous roles as Chief Medical Officer at Vir Biotechnology, Sonoma Biotherapeutics, and FibroGen, as well as 11 years at Genentech/Roche. The appointment is expected to strengthen Jade's advancement of its pipeline of antibody-based therapies for autoimmune diseases.

Benzinga

Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall As House Challenges Trump's Military Authority— Broadcom, CrowdStrike In Focus (UPDATED)

U.S. stock futures showed mixed performance on Thursday with the S&P 500 and Nasdaq 100 declining while the Dow Jones gained. Key movers included CrowdStrike surging on a 4-for-1 stock split announcement, Broadcom falling despite beating earnings estimates, and PVH plummeting after disappointing guidance. The House passed a war powers resolution challenging Trump's military authority in a rare bipartisan vote. BlackRock maintains an optimistic outlook on U.S. equities driven by AI sector strength and resilient corporate earnings.

GlobeNewswire Inc.

Jade Biosciences Announces Pricing of Public Offering of Common Stock

Jade Biosciences (Nasdaq: JBIO), a clinical-stage biotech company focused on autoimmune diseases, announced the pricing of a public offering of 10 million shares at $15.00 per share, raising $150 million in gross proceeds. The offering is expected to close on June 5, 2026, with net proceeds to be used for clinical trials, preclinical studies, manufacturing, and R&D activities. Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers.

GlobeNewswire Inc.

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

Jade Biosciences reported positive interim Phase 1 results for JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy treatment. The drug demonstrated ~70% IgA reductions sustained at 12 weeks with a favorable safety profile and potential for every-12-week dosing. Phase 2 trials are underway with Phase 3 expected to initiate in H1 2027.

GlobeNewswire Inc.

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences announced the appointment of Edward R. Conner, M.D., as Chief Medical Officer effective April 22, 2026. As part of the appointment, Dr. Conner received 500,000 non-qualified stock options with an exercise price of $25.38 per share, vesting over four years. The company is a clinical-stage biotech focused on autoimmune disease therapies with lead candidate JADE101 targeting APRIL for immunoglobulin A nephropathy treatment.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.